Description: Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Home Page: www.kancera.com
Karolinska Institutet Science Park
Solna,
171 65
Sweden
Phone:
46 8 50 12 60 80
Officers
| Name | Title |
|---|---|
| Mr. Peter Selin | Chief Executive Officer |
| Dr. Thomas Olin Ph.D. | Executive VP & Director |
| Mr. Hans Richter | Chief Financial Officer |
| Dr. Robert Edfors | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.241 |
| Price-to-Sales TTM: | 170.7225 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |